Skip to Content
  • Previous Rank
    -
  • Revenue 3 Yr Annual Growth Rate
    33%
  • Revenue 3 Yr Growth Rank
    45
  • EPS 3 Yr Annual Growth Rate
    38%
  • EPS 3 Yr Growth Rank
    51
  • Total Return 3 Yr Annual Rate
    20%
  • Total Return 3 Yr Rank
    61

With four FDA-approved drugs, this biotech firm based in Tarrytown, N.Y., has seen its share price surge as much as 40% this year.

Company Information

Revenue and net income for the four quarters ended on or before April 30, 2017. Total return for the period ended June 30, 2017.
Location
Tarrytown, N.Y.
Industry
Pharmaceuticals
Sector
Health Care
Current Streak-
Years on List1
CEO
Leonard Schleifer
Websitehttp://www.regeneron.com
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Revenue, Net Income

Revenue past four quarters ($M)$4,979
Net Income past four quarters ($M)$963

Growth Rates and Ranks

Revenue 3 Yr Growth Rank45
Revenue 3 Yr Annual Growth Rate33%
EPS 3 Yr Growth Rank51
EPS 3 Yr Annual Growth Rate38%
Total Return 3 Yr Rank61
Total Return 3 Yr Annual Rate20%
Beat S&P 500 (9.6%)
yes
P/E Ratio45